



**THE FOUNDATION  
FOR SECURE  
MARKETS**

**#47680**

**DATE: OCTOBER 5, 2020**

**SUBJECT: ADURO BIOTECH, INC. – NAME/SYMBOL/CUSIP CHANGE**  
**OPTION SYMBOLS: ADRO/ADRO1**  
**NEW SYMBOLS: KDNY/KDNY1**  
**DATE: 10/6/20**

The Options Clearing Corporation (OCC) has been informed that Aduro Biotech, Inc. (ADRO) will change its name, trading symbol and CUSIP to Chinook Therapeutics (KDNY) 16961L106, effective October 6, 2020. As a result, option symbols ADRO/ADRO1 will change to KDNY/KDNY1 effective at the opening of business on October 6, 2020.

Strike prices and all other option terms will not change. Clearing Member input to OCC must use the new option symbols KDNY/KDNY1 commencing October 6, 2020.

DATE: October 6, 2020.

OPTION SYMBOLS: ADRO changes to KDNY  
 ADRO1 changes to KDNY1 (ADRO options were adjusted on October 2, 2020. See OCC Information Memo #47665)

UNDERLYING SECURITY: ADRO changes to KDNY

CONTRACT MULTIPLIER: 1

STRIKE DIVISOR: 1

NEW MULTIPLIER: 100

DELIVERABLE PER CONTRACT: **KDNY**  
 100 Chinook Therapeutics, Inc. (KDNY) Common Shares  
**KDNY1**  
 20 Chinook Therapeutics, Inc. (KDNY) Common Shares

CUSIP: 16961L106

**DISCLAIMER**

This Information Memo provides an unofficial summary of the terms of corporate events affecting listed options or futures prepared for the convenience of market participants. OCC accepts no responsibility for the accuracy or completeness of the summary, particularly for information which may be relevant to investment decisions. Option or futures investors should independently ascertain and evaluate all information concerning this corporate event(s).

The determination to adjust options and the nature of any adjustment is made by OCC pursuant to OCC By-Laws, Article VI, Sections 11 and 11A. The determination to adjust futures and the nature of any adjustment is made by OCC pursuant to OCC By-Laws, Article XII, Sections 3, 4, or 4A, as applicable. For both options and futures, each adjustment decision is made on a case by case basis. Adjustment decisions are based on information available at the time and are subject to change as additional information becomes available or if there are material changes to the terms of the corporate event(s) occasioning the adjustment.

**ALL CLEARING MEMBERS ARE REQUESTED TO IMMEDIATELY ADVISE ALL BRANCH OFFICES AND CORRESPONDENTS ON THE ABOVE.**

For questions regarding this memo, call Investor Services at 1-888-678-4667 or email [investorservices@theocc.com](mailto:investorservices@theocc.com). Clearing Members may contact Member Services at 1-800-544-6091 or, within Canada, at 1-800-424-7320, or email [memberservices@theocc.com](mailto:memberservices@theocc.com).